We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Court Blocks Israeli Co. From Suing Amgen

Law360 (January 30, 2007, 12:00 AM EST) -- Notching a win for Amgen Inc. in a protracted patent dispute over its arthritis drug Enbrel, a U.S. federal appeals court has found that an Israeli company cannot collect royalties on the treatment.

The U.S. Court of Appeals for the Federal Circuit ruled Monday that Israel Bio-Engineering Project (IBEP) did not have standing to bring a patent infringement suit against Amgen because it could not pin down the sole ownership of the patent.

On the surface, the disagreement involved a protein used to remedy rheumatoid arthritis...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.